Illustrative image – not actual.On 14 March, 2026, Union Minister Jitendra Singh has laid the foundation stone for a Rs 600 crore pharmaceutical manufacturing facility in Kathua district, Jammu and Kashmir, aimed at strengthening India’s capabilities in antibiotic production.
The project, being developed at village Gadadhar by Orchid Pharma with support from the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology, will focus on producing amino cephalosporanic acid (ACA), a key intermediate used in the manufacture of cephalosporin antibiotics. The facility is being established under the Government of India’s Production-Linked Incentive (PLI) scheme, which aims to boost domestic manufacturing and reduce dependence on imports of critical pharmaceutical ingredients. Once operational, the project is expected to generate around 400 direct jobs and create a similar number of indirect employment opportunities in related sectors such as logistics and supply services.
The initiative is also expected to strengthen the pharmaceutical ecosystem in the region, positioning Kathua as a potential hub for antibiotic manufacturing while contributing to India’s broader goal of improving self-reliance in the pharmaceutical sector.
